Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 4/20 | 0.37 |
| ▸ | BRD4 | O60885 | 8/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3353589 | 0.87 | BRD4 (0.35) | PDPK1HTR6BRD4PTPN11 | |
| SCHEMBL13505038 | 0.85 | PDPK1 (0.45) | PDPK1HTR6BRD4PTPN11GRM2 | |
| SCHEMBL3346622 | 0.85 | BRD4 (0.36) | PDPK1HTR6BRD4TTKMAPK8 | |
| SCHEMBL13504982 | 0.82 | BRD4 (0.36) | PDPK1HTR6BRD4PTPN11 | |
| SCHEMBL3355084 | 0.82 | BRD4 (0.52) | HTR6BRD4 | |
| SCHEMBL2750994 | 0.80 | PDPK1 (0.54) | PDPK1HTR6BRD4PTPN11 | |
| SCHEMBL8192188 | 0.80 | PDPK1 (0.47) | PDPK1HTR6BRD4PTPN11GRM2 | |
| SCHEMBL2752683 | 0.80 | PDPK1 (0.47) | PDPK1HTR6BRD4PTPN11GRM2 | |
| SCHEMBL3346632 | 0.79 | PDPK1 (0.45) | PDPK1HTR6BRD4GRM2 | |
| SCHEMBL13505060 | 0.78 | HTR6 (0.46) | PDPK1HTR6BRD4TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | NFKBIA, CHUK, MAP3K1 | PDPK1 166/4885HTR6 1614/4885BRD4 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.